Martina Rupertová

Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.

E. Frei, M. Stiborová, H. Ryšlavá, 2007, Toxicology.

Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.

Eva Frei, E. Frei, M. Stiborová, 2006, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, through Metabolism to 13-Hydroxyellipticine and Ellipticine N2-Oxide

J. Hudeček, E. Frei, M. Stiborová, 2004, Cancer Research.

Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.

E. Frei, M. Stiborová, M. Rupertová, 2011, Biochimica et biophysica acta.

Monitoring of DNA adducts in humans and 32P-postlabelling methods. A review

E. Frei, M. Stiborová, H. Schmeiser, 2004 .

Biomonitoring of Human DNA Adducts Biomonitoring of Human DNA Adducts Biomonitoring of Human DNA Adducts Biomonitoring of Human DNA Adducts Biomonitoring of Human DNA Adducts

E. Frei, M. Stiborová, H. Schmeiser, 2003 .

Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.

J. Hudeček, E. Frei, M. Stiborová, 2006, General physiology and biophysics.

Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.

R. Kizek, Václav Martínek, E. Frei, 2012, Chemical research in toxicology.

Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA.

J. Hudeček, E. Frei, M. Stiborová, 2008, Neuro endocrinology letters.